Targeting the Untargeted: Emerging Targeted Therapies in Metastatic Melanoma Beyond BRAF/MEK Inhibitors.
The therapeutic landscape of advanced melanoma has been transformed by immune checkpoint inhibitors and BRAF/MEK inhibitors, resulting in substantial improvements in response rates and overall survival. However, both primary and acquired resistance remain frequent, commonly driven by MAPK pathway reactivation and activ...